ENZN
Price
$0.08
Change
+$0.01 (+14.29%)
Updated
Jul 31 closing price
Capitalization
5.92M
LPCN
Price
$3.16
Change
-$0.07 (-2.17%)
Updated
Aug 1, 04:23 PM (EDT)
Capitalization
17.34M
Interact to see
Advertisement

ENZN vs LPCN

Header iconENZN vs LPCN Comparison
Open Charts ENZN vs LPCNBanner chart's image
Enzon Pharmaceuticals
Price$0.08
Change+$0.01 (+14.29%)
Volume$41.68K
Capitalization5.92M
Lipocine
Price$3.16
Change-$0.07 (-2.17%)
Volume$146
Capitalization17.34M
ENZN vs LPCN Comparison Chart in %
Loading...
ENZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENZN vs. LPCN commentary
Aug 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENZN is a Hold and LPCN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 01, 2025
Stock price -- (ENZN: $0.08 vs. LPCN: $3.24)
Brand notoriety: ENZN and LPCN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENZN: 51% vs. LPCN: 17%
Market capitalization -- ENZN: $5.92M vs. LPCN: $17.34M
ENZN [@Biotechnology] is valued at $5.92M. LPCN’s [@Biotechnology] market capitalization is $17.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $223.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENZN’s FA Score shows that 1 FA rating(s) are green whileLPCN’s FA Score has 0 green FA rating(s).

  • ENZN’s FA Score: 1 green, 4 red.
  • LPCN’s FA Score: 0 green, 5 red.
According to our system of comparison, LPCN is a better buy in the long-term than ENZN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENZN’s TA Score shows that 3 TA indicator(s) are bullish while LPCN’s TA Score has 5 bullish TA indicator(s).

  • ENZN’s TA Score: 3 bullish, 6 bearish.
  • LPCN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LPCN is a better buy in the short-term than ENZN.

Price Growth

ENZN (@Biotechnology) experienced а -7.80% price change this week, while LPCN (@Biotechnology) price change was -2.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.03%. For the same industry, the average monthly price growth was +16.39%, and the average quarterly price growth was +36.61%.

Reported Earning Dates

ENZN is expected to report earnings on May 09, 2025.

LPCN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+1.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LPCN($17.3M) has a higher market cap than ENZN($5.92M). LPCN YTD gains are higher at: -33.607 vs. ENZN (-48.879). ENZN has higher annual earnings (EBITDA): -2M vs. LPCN (-6.42M). ENZN has more cash in the bank: 45M vs. LPCN (19.7M). LPCN has less debt than ENZN: LPCN (1.48M) vs ENZN (116M). LPCN has higher revenues than ENZN: LPCN (3.68M) vs ENZN (26K).
ENZNLPCNENZN / LPCN
Capitalization5.92M17.3M34%
EBITDA-2M-6.42M31%
Gain YTD-48.879-33.607145%
P/E Ratio96.10N/A-
Revenue26K3.68M1%
Total Cash45M19.7M228%
Total Debt116M1.48M7,827%
FUNDAMENTALS RATINGS
ENZN vs LPCN: Fundamental Ratings
ENZN
LPCN
OUTLOOK RATING
1..100
5122
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
9663
P/E GROWTH RATING
1..100
1096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LPCN's Valuation (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for ENZN (83) in the Biotechnology industry. This means that LPCN’s stock grew somewhat faster than ENZN’s over the last 12 months.

LPCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ENZN (100) in the Biotechnology industry. This means that LPCN’s stock grew similarly to ENZN’s over the last 12 months.

LPCN's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as ENZN (96) in the Biotechnology industry. This means that LPCN’s stock grew similarly to ENZN’s over the last 12 months.

LPCN's Price Growth Rating (63) in the Pharmaceuticals Other industry is somewhat better than the same rating for ENZN (96) in the Biotechnology industry. This means that LPCN’s stock grew somewhat faster than ENZN’s over the last 12 months.

ENZN's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for LPCN (96) in the Pharmaceuticals Other industry. This means that ENZN’s stock grew significantly faster than LPCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENZNLPCN
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 18 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ENZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LPCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QTTB2.240.17
+8.21%
Q32 Bio
TLX13.570.07
+0.52%
Telix Pharmaceuticals Ltd.
AIG77.630.22
+0.28%
American International Group
MGIC20.71-0.08
-0.38%
Magic Software Enterprises Ltd
MASS6.55-0.40
-5.76%
908 Devices

ENZN and

Correlation & Price change

A.I.dvisor tells us that ENZN and LPCN have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENZN and LPCN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENZN
1D Price
Change %
ENZN100%
+17.87%
LPCN - ENZN
24%
Poorly correlated
-2.70%
CLDX - ENZN
9%
Poorly correlated
-3.64%
HALO - ENZN
7%
Poorly correlated
-0.18%
INCY - ENZN
4%
Poorly correlated
-3.43%
TECH - ENZN
4%
Poorly correlated
-5.18%
More

LPCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LPCN has been loosely correlated with SPRY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if LPCN jumps, then SPRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LPCN
1D Price
Change %
LPCN100%
-2.70%
SPRY - LPCN
63%
Loosely correlated
-1.15%
IPA - LPCN
43%
Loosely correlated
-5.46%
ZNTL - LPCN
36%
Loosely correlated
+0.72%
JANX - LPCN
31%
Poorly correlated
-0.87%
TARA - LPCN
30%
Poorly correlated
-2.67%
More